[A26-43] Iptacopan (paroxysmale nächtliche Hämoglobinurie) - Addendum zum Projekt A25-156
Last updated 05.06.2026
Project no.:
A26-43
Commission:
Commission awarded on 28.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Adults with paroxysmal nocturnal haemoglobinuria (PNH)
Result of dossier assessment:
- Patients with haemolytic anaemia who are treatment-naive: unchanged after addendum: added benefit not proven
- Patients who still have haemolytic anaemia and have received prior treatment: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-43
| Project no. | Title | Status |
|---|---|---|
| A25-156 | Iptacopan (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision